These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 32125468)
1. Treatment strategy in a patient showing borderline features between plasmablastic lymphoma and plasmablastic myeloma harboring a 17p deletion. Yoshihara K; Yoshihara S; Matsuda I; Imado T; Matsuo S; Okada M; Shimizu Y; Hirota S; Fujimori Y Ann Hematol; 2020 Jun; 99(6):1405-1407. PubMed ID: 32125468 [No Abstract] [Full Text] [Related]
2. Plasmablastic lymphoma versus plasmablastic myeloma: an ongoing diagnostic dilemma. Ahn JS; Okal R; Vos JA; Smolkin M; Kanate AS; Rosado FG J Clin Pathol; 2017 Sep; 70(9):775-780. PubMed ID: 28249941 [TBL] [Abstract][Full Text] [Related]
3. Outcomes of multiple myeloma patients with del 17p undergoing autologous stem cell transplantation. Vaxman I; Visram A; Kapoor P; Kumar S; Dispenzieri A; Buadi F; Dingli D; Muchtar E; Gonsalves W; Rajkumar V; Kourelis T; Warsame R; Lacy M; Gertz MA Am J Hematol; 2021 Jan; 96(1):E35-E38. PubMed ID: 33068019 [No Abstract] [Full Text] [Related]
4. Extramedullary sarcomatoid variant of plasmablastic plasmacytoma. Majhi U; Sundersingh S; Murhekar K; Radha K J Cancer Res Ther; 2017; 13(6):1078-1079. PubMed ID: 29237987 [No Abstract] [Full Text] [Related]
5. Plasmablastic myeloma in Taiwan frequently presents with extramedullary and extranodal mass mimicking plasmablastic lymphoma. Chen BJ; Yuan CT; Yang CF; Ho CH; Lin YK; Su YZ; Chou HC; Chuang SS Virchows Arch; 2022 Aug; 481(2):283-293. PubMed ID: 35657404 [TBL] [Abstract][Full Text] [Related]
6. Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma. Merz M; Hielscher T; Seckinger A; Hose D; Mai EK; Raab MS; Goldschmidt H; Jauch A; Hillengass J Am J Hematol; 2016 Nov; 91(11):E473-E477. PubMed ID: 27508939 [TBL] [Abstract][Full Text] [Related]
7. 17P deleted multiple myeloma presenting with intracranial disease: durable remission after tailored management. Lee J; Smith D; Rabin N; Tobias J; Yong K Hematol Oncol; 2016 Sep; 34(3):165-70. PubMed ID: 26073569 [TBL] [Abstract][Full Text] [Related]
8. [Plasmablastic lymphoma presenting clinical symptoms similar to plasmablastic myeloma]. Nakaya A; Nagate Y; Toda J; Yamashita Y; Hirose Y; Mori K; Shibayama H Rinsho Ketsueki; 2023; 64(4):260-264. PubMed ID: 37121769 [TBL] [Abstract][Full Text] [Related]
9. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Lodé L; Eveillard M; Trichet V; Soussi T; Wuillème S; Richebourg S; Magrangeas F; Ifrah N; Campion L; Traullé C; Guilhot F; Caillot D; Marit G; Mathiot C; Facon T; Attal M; Harousseau JL; Moreau P; Minvielle S; Avet-Loiseau H Haematologica; 2010 Nov; 95(11):1973-6. PubMed ID: 20634494 [TBL] [Abstract][Full Text] [Related]
10. Bone marrow infiltration by plasmablastic neoplasm: plasmablastic myeloma or plasmablastic lymphoma? Eladl E; Chang H Blood; 2021 Mar; 137(9):1268. PubMed ID: 33661296 [No Abstract] [Full Text] [Related]
11. Successful Use of Bortezomib-Lenalidomide Combination as Treatment for a Patient With Plasmablastic Lymphoma. Marrero WD; Cruz-Chacón A; Castillo C; Cabanillas F Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):e275-e277. PubMed ID: 29753690 [No Abstract] [Full Text] [Related]
12. SLAMF7 (CD319/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target. Shi J; Bodo J; Zhao X; Durkin L; Goyal T; Meyerson H; Hsi ED Br J Haematol; 2019 Apr; 185(1):145-147. PubMed ID: 29785767 [No Abstract] [Full Text] [Related]
13. Heterogeneity in the diagnosis of plasmablastic lymphoma, plasmablastic myeloma, and plasmablastic neoplasm: a scoping review. Mori H; Fukatsu M; Ohkawara H; Oka Y; Kataoka Y; Taito S; Ikezoe T Int J Hematol; 2021 Dec; 114(6):639-652. PubMed ID: 34462886 [TBL] [Abstract][Full Text] [Related]
14. Follicular lymphoma suggested to transform into EBV-negative plasmablastic lymphoma. Yamada T; Hara T; Goto N; Iwata H; Tsurumi H Int J Hematol; 2019 Jun; 109(6):723-730. PubMed ID: 30859398 [TBL] [Abstract][Full Text] [Related]